AVEO Oncology to Participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit
May 01 2019 - 7:00AM
Business Wire
AVEO Oncology (NASDAQ:AVEO) today announced that members of the
management team will participate in the 5th Annual SunTrust
Robinson Humphrey Life Sciences Summit on Wednesday, May 8, 2019.
The conference is being held May 7-8 in New York.
About AVEO
AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a
biopharmaceutical company seeking to advance targeted medicines for
oncology and other unmet medical needs. The Company is working to
develop and commercialize its lead candidate tivozanib in North
America as a treatment for RCC. The Company has sublicensed
tivozanib (FOTIVDA®) for oncological indications in Europe and
other territories outside of North America. Tivozanib is approved
in the European Union, as well as Norway and Iceland, for the
first-line treatment of adult patients with RCC and for adult
patients who are vascular endothelial growth factor receptor and
mTOR pathway inhibitor-naïve following disease progression after
one prior treatment with cytokine therapy for RCC. The Company also
has clinical collaborations to study tivozanib in combination with
immune checkpoint inhibitors in RCC and in hepatocellular
carcinoma. In addition, a new formulation of tivozanib is in
preclinical development for the treatment of age-related macular
degeneration. As part of the Company’s strategy, the Company has
also entered into partnerships to help fund the development and
commercialization of its other product candidates. Ficlatuzumab, a
hepatocyte growth factor inhibitory antibody, is currently being
tested in several investigator sponsored studies jointly funded by
the Company and its development partner for the potential treatment
of squamous cell carcinoma of the head and neck, AML, and
pancreatic cancer. The Company’s partner for AV-203, an anti-ErbB3
monoclonal antibody, is planning to initiate clinical studies in
China in 2019 in esophageal squamous cell carcinoma and has
committed to funding the development of AV-203 through
proof-of-concept. The Company has recently regained the rights to
AV-380, a humanized IgG1 inhibitory monoclonal antibody targeting
growth differentiation factor 15, a divergent member of the TGF-ß
family, for the potential treatment of cancer cachexia, and is
working to initiate preclinical toxicology studies in 2019 to
support the potential filing of an investigational new drug
application with the FDA. The Company is evaluating options for the
development of its preclinical AV-353 program which targets the
Notch 3 pathway.
For more information, please visit the Company’s website at
www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
that involve substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Actual results or events
could differ materially due to a number of important factors,
including risks discussed in the section titled “Risk Factors” in
AVEO’s most recent Annual Report on Form 10-K, its quarterly
reports on Form 10-Q and its other filings with the SEC. The
forward-looking statements in this press release represent AVEO’s
views as of the date of this press release. AVEO anticipates that
subsequent events and developments may cause its views to change.
While AVEO may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. You should, therefore, not rely on these forward-looking
statements as representing AVEO’s views as of any date other than
the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190501005153/en/
AVEO:David Pitts, Argot Partners(212)
600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Sep 2023 to Sep 2024